











































Conventional cancer therapies involve the use of 
combinations of surgery, radiotherapy and various 
chemotherapeutic regimens. The anthracyclines 
represent an extremely effective class of chemo-
therapeutics which are used for the treatment of 
numerous haematological and solid malignancies [1]. 
They have been shown to induce cancer cell-death by a 
number of mechanisms including DNA binding and 
intercalation, generation of free radicals, inhibition of 
the topoisomerase II enzyme  and damage  to cell  mem- 
 
 









































branes [2-4].  In addition, anthracyclines have been 
shown to modulate various signalling pathways 
including those involved with apoptosis [5, 6].  The 
most potent and widely used anthracycline is 
doxorubicin, an analogue that has potent broad-
spectrum antineoplastic activity and has been used a 
frontline cancer chemotherapeutic for several decades 
[7].  However, the clinical application of doxorubicin is 
limited by cumulative, dose-dependent cardiotoxicity 
[8]. For example, clinical trials have indicated that 7% 
of patients treated with doxorubicin experience a 
































will  be  most  effective  when  used  in  combination  with  conventional  cancer  therapies,  such  as  the  anthracycline,
doxorubicin.  The  dose‐limiting  side  effect  of  doxorubicin  is  severe  cardiotoxicity  and  evaluation  of  the  effects  of
combinations of the anthracycline with histone deacetylase inhibitors in relevant models is important.  We used a well‐
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550 mg/m
2 [9]. The various cardiomyopathies, 
including cardiac hypertrophy, that are associated with 
doxorubicin treatment are well known and have been 
described extensively [10-13].  
 
Histone deacetylase (HDAC) inhibitors represent a new 
class of anticancer therapeutics. The first clinical 
compound is the hydroxamic acid, suberoylanilide 
hydroxamic acid (SAHA; Vorinostat) which has been 
approved by the US FDA for the treatment of cutaneous 
T-cell lymphoma (CTCL) [14, 15].  Further, several 
HDAC inhibitors are currently undergoing evaluation in 
clinical trials and encouraging antineoplastic effects at 
well-tolerated doses have been observed in both 
haematological and solid cancers [14, 15]. The effects 
of HDAC inhibitors are due to numerous mechanisms 
including, induction of differentiation, cell cycle arrest, 
production of reactive oxygen species, altered cell 
migration, mitotic and autophagic cell death, and 
induction apoptosis in cancer cell-lines in culture and in 
vivo [16-19].   Studies have shown that the cytotoxic 
and more recently the DNA damaging effects of HDAC 
inhibitors is much more pronounced in malignant or 































For cancer therapy, it is expected that HDAC inhibitors  
will be particularly useful when used in combination with 
conventional therapeutics [16, 21-23].  Indeed, 
combinations of various HDAC inhibitors with 
radiotherapy or chemotherapeutics, including doxo-
rubicin, have been widely investigated and synergistic or 
at least additive effects have been observed [24-31]. 
Given this emerging therapeutic strategy, it is important 
to evaluate the effects of combinations of HDAC 
inhibitors with conventional cytotoxic agents in relevant 
models to identify and investigate potential clinical side 
effects. Since cardiomyopathy is the most severe side 
effect of doxorubicin treatment, we evaluated the effects 
of combinations of the anthracycline with Trichostatin A, 
the prototypical broad-spectrum HDAC inhibitor, in 
cardiomyocytes [32].  An established cell culture 
approach of doxorubicin-induced cardiac hypertrophy in 
rat H9c2 ventricular myocardial cells was used as a 
model system [33].  Firstly, we evaluated the effects of 
doxorubicin on the expression of the hypertrophy-
associated genes, ventricular myosin light chain-2 (MLC-
2v), the alpha isoform of myosin heavy chain (α-MHC) 
and atrial natriuretic peptide (ANP) [34-38].  The effects 
of Trichostatin A on doxorubicin-induced hypertrophic 
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H9c2 myoblasts differentiate to cardiac myocytes in 
the presence of retinoic acid 
 
It is well-established that chronic culture in low serum 
media containing all-trans-retinoic acid prevents 
transdifferentiation of embryonic cardiac H9c2 cells 
into skeletal muscle [39]. We confirmed the phenotype 
of embryonic myoblasts and monitored myogenesis and 
cardiac myocyte formation by phase contrast 
microscopy and RT-PCR (Figure 1).  Freshly plated 
cells maintained in media containing 10% FBS were 
strictly mononucleated myoblasts that trans-
differentiated into skeletal muscle cells, as observed by 
the parallel and regular elongated bundles, following a 
seven day culture in media containing 1% FBS (Figures 
1A and 1B).  Culture of H9c2 myoblasts in low serum 
media and stimulation with 10 nM all-trans-retinoic 
acid for seven days resulted in the maintenance of the 
cardiac phenotype with the elongated cells connecting 
at irregular angles (Figure 1C).  Further confirmation of 
the cardiac phenotype was obtained by investigating the 
relative expression levels of MLC-2v, a gene which 
displays absolute cardiac tissue specificity [40].  The 
RT-PCR findings indicate a four-fold increase in the 
expression of MLC-2v in cells cultured in low serum 
media containing 10 nM all-trans-retinoic acid 
compared to cells cultured in low serum media without 

























Doxorubucin induces a hypertrophic response in 
H9c2 cardiac myocytes 
 
The dose-dependent hypertrophic response in H9c2 
cells induced by treatment with doxorubicin was 
examined by measuring the cell volume and total 
protein content (Figures 2A and 2B). Experiments 
involved incubating cells with various concentrations 
(0-2  μM) of doxorubicin for two hours followed a 
further incubation in fresh media for a further 24 hours. 
The findings indicated a dose-dependent increase in cell 
volume and total protein content up to a concentration 
of 1 μM doxorubicin. The change in phenotype and 
enlargement of H9c2 cardiomyocytes treated with 1 μM 
doxorubicin is also evident by phase-contrast 
microscopy (Figures 2C and 2D). 
 
Doxorubicin modulates the expression of 
hypertrophy-associated genes in cardiomyocytes 
 
To further characterise the response of H9c2 cells to 
treatment with doxorubicin, the relative expression levels 
of well known cardiac hypertrophy-associated genes, 
namely MLC-2v, α-MHC and ANP, was examined by 
RT-PCR (Figure 3).  The findings indicated a dose-
dependent increase in the expression of MLC-2v and 
ANP which are known to be upregulated in cardiac 
hypertrophy [34-36].  Furthermore, doxorubicin induced 
a dose-dependent decrease in the relative expression of 
α-MHC representing another established hallmark of 













































































































































Figure  3.  Doxorubicin  modulates  the  expression  of  cardiac  hypertrophy‐associated  genes  in  H9c2










shown  relative  to  untreated  control  H9c2  cells;  mean  ±  standard  deviations  of  triplicates  from  a
representative experiment (total of three independent experiments) are indicated. 
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hypertrophy in H9c2 cardiac myocytes 
 
We investigated the effects of the prototypical and 
potent, broad-spectrum histone deacetylase inhibitor, 
Trichostatin A, on doxorubicin-induced hypertrophic 
responses in H9c2 cells.  Firstly, we investigated the 
effects of a 24 hour exposure to 1 μM Trichostatin A 
alone, on the relative expression levels of MLC-2v, α-
MHC and ANP.  The findings indicate that Trichostatin 
A alone causes a significant modulation of MLC-2v and 
α-MHC gene expression, inducing a hypertrophic 
response in H9c2 cells (Figure 4).  In addition, exposure 
of the cells to a combination of Trichostatin A and 
doxorubicin results in a greater increase in the relative 
expression of the MLC-2v and a greater decrease in the 
expression of α-MHC, compared to treatment with 
either compound alone (Figure 4). In contrast, exposure 
of the cells to 1 μM Trichostatin A for 24 hours does 
not result in the modulation of the ANP gene. 
Furthermore, the results indicate that Trichostatin A 
does not affect the significant increase in ANP 
expression observed when cells are exposed to 1 μM 
































Trichostatin A enhances doxorubin-induced DNA 
damage in cardiomyocytes 
 
Having established that the inhibition of histone 
deacetylase increases doxorubisin-induced hypertrophy, 
we determined whether the effect of TSA on 
cardiomyocytes conferred changes in DNA damage. 
Phosphorylation of the histone variant, H2AX on Ser-
139 forming γH2AX, is a sensitive and reliable marker 
of DNA double-strand breaks [41, 42].  Therefore, we 
utilised this phosphorylation event to evaluate the 
effects of Trichostatin A on doxorubicin-induced DNA 
damage (Figure 5).  Quantitation of γH2AX foci 
indicated that a one hour incubation with 1 μM 
doxorubicin, followed by 24 hour incubation in fresh 
media, results in the formation of a significant number 
of DNA double-strand breaks – approximately 26 foci 
per cell compared to an average of approximately 2 foci 
per cell in untreated cells (Figures 5A, 5Bi and 5Biii).  
The findings also indicate a modest dose-dependent 
increase in γH2AX foci following 24 hour incubation 
with Trichostatin A (Figure 5A).  Importantly, the 
results show a significant enhancement of doxorubicin-
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deacetylase inhibitor may augment doxorubicin-induced 




Our findings indicate that Trichostatin A augments 
doxorubicin-induced cardiac hypertrophy and DNA 
double-strand induction in H9c2 cardiac myocytes.   We 
used clonal embryonic ventricular H9c2 myoblasts that 
have been isolated and established by selective 
passaging from BDIX rat heart tissue for our 
investigation [43]. This cell line is used widely given 
the ease of manipulation of the cells and the ability to 
maintain the cardiac phenotype in the presence retinoic 
acid has been well defined [39].  In accordance, with 
previous studies, we confirmed maintenance of the 
cardiac phenotype in the presence of retinoic acid and 
examined transdifferentiation of H9c2 myoblasts to 
skeletal muscle, following culture in low serum media 
without retinoic acid [39].  Furthermore, doxorubicin-
induced cardiac hypertrophy is well-characterized in 
H9c2 cells, which is of importance for our 
investigations [33, 44]. 
 
Cardiac hypertrophy, defined as an increase in 
cardiomyocyte size, is an adaptive response to a number 
of intrinsic (e.g. mutations of sarcomeric contractile 
proteins in familial hypertrophic cardiomyopathy) and 
extrinsic stimuli (e.g. hypertension).  It is characterized 
by increased protein synthesis, sarcomeric 
reorganization and re-expression of fetal regulatory 
genes.  Prolonged pathological cardiac hypertrophy is a 
major cardiovascular endpoint and is strongly 
associated with arrhythmias, heart failure and sudden 
death.  Doxorubicin is thought to induce cardiac 
hypertrophy, a dose-limiting side effect, by the 
formation of free-radicals and lipid peroxidation [45].  
This has lead to numerous investigations into the 
potential of free radical scavengers to ameliorate the 
effects of doxorubicin and more recently liposomal and 
nanoparticle-based formulations of the drug have been 
prepared [46-50]. In this context, an important link 
between cell growth, senescence and hypertrophy has 
been suggested and it has been previously shown that 
doxorubicin-induced hypetrophy and senescence can be 
inhibited by the immunosupresant, rapamycin [51-53]. 
 
In H92 cells, doxorubicin has been shown to induce a 
hypertrophic response and this has been associated with 
increased protein content and with morphological 
changes which have been correlated with increases in 
cell size and apoptosis [33, 44].   Therefore, these cells 
have been used extensively to investigate doxorubicin-
induced cardiotoxicity and to evaluate the effectiveness 
of protective compounds including, carvedilol, 
rosmarinic acid and thromobopoietin [54-57].  Our 
findings, are similar to those previously published and 
indicate a dose-dependent increase in cell size and 
protein in H9c2 myocytes following treatment with 
doxorubicin (Figure 2) [33, 44].  In addition, there has 
been an increase in our understanding of molecular 
pathways associated with doxorubicin-induced 
cardiotoxicity in H9c2 cells.  Since reinduction of the 
fetal cardiac gene program is known to be a hallmark of 
cardiac hypertrophy, we investigated the effects of 
doxorubicin on expression of the MLC-2v, α-MHC and 
ANP genes [58].  These serve as well-established 
markers of cardiac hypertrophy [34-38, 58].  In 
accordance with our expectations the findings indicate 
that a dose-dependent doxorubicin-induced increase in 
MLC-2v and ANP expression and a decrease in α-MHC 
expression (Figure 3).  The result for ANP is consistent 
with a previous findings indicating that doxorubicin 
causes an induction of the hypertrophic markers, ANP 
and beta natriuretic peptide [59]. 
 
The antineoplastic properties of HDAC inhibitors are 
caused, at least in part, by the accumulation of 
acetylated nuclear core histones resulting in the altered 
transcription of a small number of genes, some of which 
important in regulating cellular proliferation, cell cycle 
progression and apoptosis [22, 23].  Moreover, the 
effects of HDAC inhibitors in malignant or transformed 
cells can be attributed to altered activity of numerous 
critical proteins including transcription factors and key 
regulators of signaling cascades [14, 15].  Furthermore, 
it is relatively well-established that HDAC inhibitors 
augment the cytotoxic effects of ionising radiation and 
chemotherapeutics, including doxorubicin, in cancer 
cells in culture and in vivo [24-31, 60, 61].   However, 
the effects of HDAC inhibitors in normal cells, and 
more specifically in cardiac hypertrophy, require 
clarification.  For example, it has been shown that class 
II HDAC enzymes suppress cardiac hypertrophy and 
this has been associated with repression of the activity 
of myocyte enhancer factor 2 [62].  However, a number 
of studies have indicated a favorable role for HDAC 
inhibitors, particularly Trichostatin A, in cardiac 
hypertrophy both in vitro and in vivo [63-65].  Of 
particular importance, a previous study has indicated 
that Trichostatin A inhibited agonist-induced 
hypertrophy in neonatal rat ventricular myocytes and 
this effect was correlated with histone hyperacetylation 
and inhibition of fetal gene expression including α-
MHC [63].  However, in that particular study a 
relatively low concentration of Trichostatin A (85 nM) 
was investigated.  Our findings using 1 μM Trichostatin 
A indicate that the HDAC inhibitor alone induces a pro-
hypertrophic response and amplifies doxorubicin-
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the higher concentration, which we have already 
determined is known to induce robust histone 
hyperacetylation and alterations in gene transcription as 
well as cell-death in malignant cells [26, 27, 66]. 
 
In addition to altering cellular morphology and 
modulating signaling pathways, doxorubicin has been 
shown to induce DNA damage and induction of p53 in 
H9c2 cells [67-69]. We investigated the effects of 
Trichostatin A on doxorubicin-induced DNA double-
strand breaks using γH2AX as a molecular marker.  Our 
findings indicate that pre-treatment of H9c2 cells with 
Trichostatin A potentiates doxorubicin mediated DNA 
damage, even at a relatively low concentrations of the 
HDAC inhibitor (100 nM, Figure 5).  Therefore, 
augmentation of initial DNA damage represents an 
additional mechanism by which HDAC inhibitors may 
enhance the cytotoxicity of conventional antineoplastic 
chemotherapeutics.    
 
Overall, histone deacetylase inhibitors have emerged as 
a new class of anticancer therapeutics, which are 
anticipated to be most effective when used in 
combination with conventional cancer therapies.   
Although they have been shown to induce cell-death 
and apoptosis preferentially in cancer and transformed 
cells compared to normal cells, the effects of 
combinations of HDAC inhibitors with other cytotoxic 
agents in normal cells have not been well-investigated.  
Our current findings which indicate that Trichostatin A 
potentiates doxorubicin-induced cardiac hypertrophy 
and DNA damage highlight the need for further 
investigation of potential side effects associated with 
new combination therapies for cancer. 
 
MATERIALS AND METHODS 
 
Cell culture, differentiation and treatment.  The rat 
embryonic ventricular myocardial, H9c2 cells were 
obtained from the American Type Culture Collection 
(Manassas, VA, USA) and were grown as monolayers 
in Dulbecco’s modified Eagle’s medium (DMEM), 
containing 10% fetal bovine serum (FBS, In Vitro 
Technologies, Victoria, Australia), 100 U//ml penicillin 
and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA, 
USA), at 37C in a humidified atmosphere with 5%CO2.  
Prior to confluence (typically 60-70%), cells were 
passaged using 0.5% trypsin-EDTA (Invitrogen) and 
centrifugation (250 x g for 5 minutes) and seeded at 
ratios of 1:2 or 1:3 in DMEM containing 10% FBS for 
24 or 48 hours.  Cells were then cultured in DMEM 
containing 1% FBS with (to maintain the cardiac 
phenotype) or without (myogenic transdifferentiation) 
10 nM all-trans-retinoic acid (Sigma-Aldrich, St. Luis, 
MO, USA) for 7 days and the culture media was 
changed daily.   
 
The experiments described below, which required 
doxorubicin (Ebewe Pharma, Unterach, Austria) and 
Trichostatin A (Sigma-Aldrich) treatment, were 
performed with cells that were cultured in 1% FBS 
containing 10 nM all-trans-retinoic acid for 7 days.  For 
experiments involving treatment with doxorubicin, cells 
were incubated with various concentrations (0-2 μM) of 
the anthracycline for 2 hours (except for the γH2AX 
immunofluorescence experiments described below; 
cells were incubated with doxorubicin for 1 hour). The 
cells were washed twice with phosphate buffered saline 
without calcium and magnesium and were incubated for 
a further 24 hours in fresh media.  For relevant 
experiments, H9c2 cells were treated with various 
concentrations of Trichostatin A (0-1 μM) for 24 hours.  
Trichostatin A was added to the media immediately 
following the 2 hour incubation with doxorubicin, 
except for the γH2AX immunofluorescence experiments 
described below, which involved a 24-hour pre-
treatment with the HDAC inhibitor prior to exposure to 
doxorubicin for 1 hour. 
 
Cell size and protein content.  Adherent cells were 
detached using 0.05% trypsin EDTA and rounded cells 
were imaged using an Olympus (CKX41, Tokyo, Japan) 
microscope and x 20 lens.  Cell diameters were 
measured using Image J (Fiji Version 1.44a) software 
and cell volume was calculated using the equation for 
the volume of a sphere (4/3 x π x radius
3). 
 
For determination of protein content, cells were 
collected by trypsinization and lysed with mammalian 
protein extraction reagent (Thermo Scientific, 
Rockford, IL, USA) and complete protease inhibitor 
cocktail (Roche, Indianapolis, IN, USA) at 4°C for 30 
minutes. The suspension was centrifuged at 13,000 x g 
for 10 minutes at 4°C and the supernatant was collected. 
Protein concentration in the total cell lysates was 
measured at 595 nm using the Bradford assay with 
bovine serum albumin standards [70]. 
 
Real-time polymerase chain reaction (RT-PCR). RNA 
was extracted from H9c2 cardiomyocytes using Trizol 
reagent (Invitrogen) and DNA was removed using the 
Turbo DNA-free™ kit (Ambion Inc., Austin, TX, USA) 
according to the manufacturer’s instructions. Total 
RNA (1 μg) was converted to cDNA using random 
primers and Moloney murine leukemia virus reverse 
transcriptase (Sigma-Aldrich). Primers were designed 
using Primer Express® Software v2.0: MLC-2v 5’- 
CCTAACGTCACCGGCAACC-3’ and 5’- 
TTTGGTTCACATCATCACCCA-3;  α-MHC, 5’-
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GGTCCCCTATGGCTGCAAT-3’; ANP, 5’- 
TCTTCCTCTTCCTGGCCTTTT-3’ and 5’- 
CGGGATTTGCTCCAATATGG-3’;  β-actin, 5’-
CCTCTGAACCCTAAGGCG-3’ and 5’-
AGGGACAACACAGCCTGGAT-3’ (Sigma-Aldrich). 
Fold changes (ΔCt) were calculated in the following 
manner: the cycle number (Ct) of the target genes were 
extrapolated using the software analysis program (SDS 
1.9, Applied Biosystems) and was subtracted from the 
Ct of the input control. All means, standard deviations 
and statistics were calculated as a fold value. 
 
γH2AX immunofluorescence.  The number of γH2AX 
foci in H9c2 cell nuclei following treatment with 
doxorubicin, Trichostatin A and combination of 
pretreatment with Trichostatin A followed by 
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